Cancer-related fatigue (CRF) has been identified as the most prevalent and distressing, yet underrecognized symptom associated with cancer and cancer treatments in adults.
Cancer-related fatigue (CRF) has been identified as the most prevalent and distressing, yet underrecognized symptom associated with cancer and cancer treatments in adults. 1 Clinical assessment of CRF has increased during the past decade. A 0 to 10 visual analog scale, such as the one incorporated in the National Comprehensive Cancer Network (NCCN) Cancer-Related Fatigue Clinical Practice Guidelines in Oncology (in this issue), has been adopted to assess this symptom in many clinical settings. 2 One major limiting factor in initiating assessment has been the lack of evidence for interventions to relieve a patient's self-reported CRF. The NCCN guidelines direct clinicians to assess treatable contributing factors, including pain, emotional distress, anemia, sleep disturbances, nutritional status, activity level, and comorbid illnesses. The guidelines also provide clinicians with information to relieve CRF through enhancing activity level and psychosocial interventions.
Clinicians may feel less prepared to intervene when an assessment shows a patient is experiencing sleep disturbances in addition to CRF. Most clinicians are unaware of how to optimize sleep quality when it presents alone or in combination with CRF and other symptoms. Therefore, this article shares current knowledge about the relationships among CRF, sleep disturbances, and daytime sleepiness, and makes recommendations for routine screening, assessment, and interventions to modify fatigue through optimizing sleep quality in adult cancer patients. Current knowledge linking CRF with sleep disturbances and daytime sleepiness is summarized, followed by a review of evidence-based nonpharmacologic and pharmacologic interventions to optimize sleep quality and impact daytime sleepiness and CRF. A summary of recommendations is provided for practice and research to optimize sleep quality and modify fatigue in adult cancer patients.
Fatigue, Sleep Disturbances, and Daytime Sleepiness in Cancer Patients
Fatigue is defined by the NCCN as a "distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning." 2 Fatigue is reported by most cancer patients who have undergone surgery, chemotherapy, or radiation therapy, 3 or have been treated with hematopoietic stem cell transplantation, hormonal therapy, or a biologic response modifier, 4 often persisting for months or years beyond completion of treatment. Fatigue rarely occurs alone; more commonly it is reported as one of several symptoms that occur in clusters. 5 This multidimensional subjective symptom has physical, emotional, sensory, and cognitive dimensions that impact functioning. Fatigue is referred to as acute when it lasts less than 4 weeks and chronic when it lasts 1 to 6 months or longer. 3 Similar to fatigue, sleep disturbances, of which insomnia is the most prevalent, have been underrecognized and undertreated in cancer patients. 6 Insomnia has been reported in 30% to 50% of cancer patients, 7 more than twice the incidence in the general public. Insomnia refers to "complaints of difficulty initiating or maintaining sleep or non-restorative sleep which lasts for at least one month and which causes clinically significant distress or impairment in social, occupational, or other important areas of functioning." 8 Diagnostic criteria for insomnia include associated daytime fatigue and significant fatigue-related distress. Quality sleep is defined as the absence of the above complaints, distress, and impairments.
Assessment is the first step in managing sleep disturbances. 9 A screening tool to detect individuals with these complaints, such as the Clinical Sleep Assessment for Adults 10 or the Insomnia Severity Index, 11 must be used in the clinical setting. When the screen is positive, sleep patterns that should be assessed include time in bed, total sleep time, sleeponset latency, number of awakenings, number of minutes awake or percent of time awake after sleep onset, daytime napping, excessive daytime sleepiness, sleep quality, and sleep efficiency. 12 Further assessment of risk factors for sleep disorders is also indicated when the screen is positive, with a focus on other symptoms, comorbid illnesses, and current medications. 13 Recommendations for a standard research assessment of insomnia disorders have been identified, and include definitions and diagnoses of insomnia and comorbid conditions; measures of sleep and insomnia, including qualitative insomnia measures, diary, polysomnography, and actigraphy; and measures of the waking correlates and consequences of insomnia disorders. 14 The Conceptual Model of Impaired Sleep 15 posits that impaired sleep can be categorized as either sleep deprivation resulting from an inadequate amount of sleep or sleep disruption that occurs secondary to fragmented sleep during the sleep period (Figure 1 ). Sleep deprivation is often the result of lifestyle and developmental factors, whereas sleep disruption is often caused by health-related conditions, including cancer. Another model, known as the 3P model, suggests that impaired sleep is related to numerous predisposing, precipitating, or perpetuating factors. 16 The specific causes of impaired sleep in patients with cancer have not been determined, but factors that contribute to disturbances in sleep regulation have been identified in healthy adults 17 and patients with cancer. 18 A neuroendocrine-based regulatory fatigue model has hypothesized that a shared origin may exist for several symptoms, including impaired sleep, fatigue, and depression, in specific cancer populations. 19 This model and several lines of study provide evidence that sleep disturbances, fatigue, and other symptoms, such as asthenia and problems with mental concentration, in cancer patients may be linked to hypothalamic-pituitary-adrenal axis overactivity and excess secretion of corticotropin-releasing factor, adrenocorticotropinreleasing hormone, and cortisol, together with diurnal variations in immunoregulatory cytokine levels and altered circadian rhythmicity. [20] [21] [22] [23] [24] [25] Growing evidence suggests that proinflammatory cytokines play a role in the origin of several chemotherapy-related symptoms. 26 Impaired sleep has also been linked to numerous adverse Health Related Quality of Life (HRQOL) outcomes in physiological, cognitivebehavioral, emotional, and social domains, as shown in Figure 1 . 15, 27 Common sleep disorders in adults include insomnia, sleep-related breathing disorders, sleep-related movement disorders, and parasomnias. 28, 29 Insomnia is a heterogeneous disorder that includes primary insomnias for which no other cause is known. 28 Primary insomnia has been termed psychophysiologic (heightened arousal and learned sleep-preventing associations); physiologic (subjective reports confirmed by objective sleep measures); and idiopathic (linked to childhood onset and a chronic inability to obtain adequate sleep). The prevalence of each type of primary insomnia has not been routinely assessed or reported in patients newly diagnosed with cancer. Another group of insomnias, traditionally referred to as secondary insomnias but recently termed comorbid insomnias, include insomnia associated with other medical disorders, such as cancer. 30 Assessment for depression is imperative, because sleep disturbances and fatigue are common manifestations of depression. 31, 32 Insomnia can be transient, transient recurring, or chronic in nature (lasting 6 months). Daytime sleepiness has been described as the likelihood of a person falling asleep during 8 phases of daily life. 33 Daytime sleepiness is a frequent complaint among cancer patients who report poor sleep, but few studies have described the prevalence and consequences of daytime sleepiness in patients with cancer.
Evidence shows that fatigue, sleep disturbances, and daytime sleepiness are associated with each other and other symptoms, but a clear understanding of the relationships among them has not been established in cancer patients. 34, 35 Recent review articles have described relationships among these variables, including the occurrence of symptom clusters, based on studies at different points along the cancer trajectory. 1, 12, [36] [37] [38] [39] [40] [41] Studies have most commonly included women with breast cancer at various times along the cancer trajectory. Consistent relationships have been found between higher CRF and more disturbed sleep before, [42] [43] [44] during, 45, 46 and after [47] [48] [49] [50] completion of chemotherapy treatments. Moderate to severe sleep maintenance problems in patients treated with chemotherapy, indicated by increased number and duration of nighttime awakenings, have been documented using wrist actigraphy. 45, 46 The relationship between fatigue and disturbed sleep in numerous dimensions has been reinforced and complimented by subjects' perceptions of their sleep as measured with reliable and valid tools, such as the Pittsburgh Sleep Quality Index. 51 A link between increased fatigue and sleep disturbances (per actigraphy) was also found in outpatients undergoing radiation therapy for bone metastasis. 52 Pain treatment with strong opioids, a feeling of hopelessness, and interference of pain with mood significantly influenced sleep quality in patients with advanced cancer. 53 Higher self-reported daytime dysfunction has been found to be associated with more disturbed sleep and higher fatigue in the 48 hours before the first adjuvant breast cancer chemotherapy treatment. 42, 43 Daytime sleepiness has seldom been reported in relation to sleep quality in cancer patients. A recent study reported a relationship between more disturbed sleep quality and higher daytime sleepiness during adjuvant breast cancer chemotherapy, as measured by the Epworth Sleepiness Scale. 46 Higher levels of CRF before and during chemotherapy treatments also have been shown in patients with breast cancer to be related to less robust circadian activity rhythms. 40, 42, 43, 45, [54] [55] [56] Components of less robust rhythms include disrupted sleep, low daytime activity levels, and a dampened range of activity over 24-hour periods. Aberrant circadian rhythms were linked to higher fatigue and marked disruption of function and HRQOL in patients with advanced cancer. 57, 58 Higher fatigue has also been identified as part of symptom clusters that include menopausal symptoms such as a hot flashes, vaginal dryness, and decreased libido; 59 pain and insomnia; 60 disturbed sleep and depression; 29, 38 disturbed sleep, pain, and anxiety/depression; 52 depression, disturbed sleep, and cognitive impairment; 61 and depressive symptoms and impaired functional status. 62 Understanding the relationships between and among symptoms has been challenging for clinicians and researchers.
Interventions to Optimize Sleep Quality and Daytime Functioning Evidence-Based Practice Guidelines
Symptom management is a key aspect of the scope of practice of the oncology nurse and an important responsibility of the entire healthcare team. The contemporary healthcare delivery system holds all clinicians accountable to provide evidence-based care that is safe and cost-effective. The American Academy of Sleep Medicine (AASM) recently published an updated summary of the evidence 63 and evidence-based practice parameters 64 relative to behavioral and psychological treatments for primary and secondary (i.e., comorbid) insomnia. The summary did not address any evidence relative to pharmacologic agents. The AASM classification of evidence, adapted from Sackett, 65 was used to grade evidence from peerreviewed scientific literature, and recommendations for practice were proposed.
The Oncology Nursing Society (ONS) developed a similar schema for grading the strength of evidence by adapting the British Medical Journal (BMJ) Clinical Evidence model. 66, 67 The report entitled, ONS Putting Evidence into Practice, refers to these resources for improving patient outcomes as "ONS PEP" resources. 68 All nonpharmacologic and pharmacologic interventions for both fatigue and sleep-wake disturbances that had been tested in cancer patients and published by December 2005 were critically reviewed, and the overall strength of the evidence was graded. 69, 70 
Nonpharmacologic Interventions
Psychological and cognitive-behavioral therapies encompass a broad group of sleep interventions that involve attenuating physiologic arousal and changing negative thought processes and attitudes about one's ability to fall asleep, stay asleep, get enough sleep, and function during the day. 71, 72 These therapies are designed to assist with sleep initiation and maintenance. Table 2 summarizes current evidence for cognitive-behavioral interventions and strategies. 73 The 2006 AASM practice parameters rated psychological and behavioral interventions as effective, and recommended them as "Standard" for the treatment of chronic primary and secondary (comorbid) insomnia. 64 This recommendation for secondary insomnia was based on 11 studies that evaluated the effects of treatment for insomnia associated with another medical or psychiatric disorder, including 4 randomized controlled trials with either level 1 74, 75 or level 2 76,77 evidence. AASM practice parameters also recommended as standard 3 specific therapies for chronic insomnia: stimulus-control therapy, relaxation training, and cognitive behavior therapy (with or without relaxation therapy). AASM rated the following therapies as "Guideline" for chronic insomnia: sleep restriction, multicomponent therapy, paradoxical intention, and biofeedback. "Insufficient Evidence" recommended sleep hygiene education as a single therapy or when incorporated into multicomponent approaches. 64 The ONS PEP resources organized sleep-wake interventions that were tested in cancer patients into 4 categories: cognitive-behavioral, complementary, psychoeducational, and exercise therapies. 70 No intervention was categorized as "Recommended for Practice" or "Likely to be Effective." Several sleep interventions reporting a positive impact on sleep were classified as "Effectiveness Not Established." No sleep intervention was classified as "Effectiveness Unlikely" or "Not Recommended for Practice." 67 The ONS PEP resources rated 5 of the cognitivebehavioral sleep intervention studies referred to above as "Likely to be Effective" for reducing fatigue in cancer patients. [78] [79] [80] [81] [82] Lower fatigue in cancer patients was also reported as a result of sleep interventions from each of the other categories of sleep interventions, including complementary, 83 psychoeducational, 84 and exercise. 85 These interventions have been shown to be effective when delivered either individually or in group settings.
Pharmacologic Interventions
Numerous pharmacologic approaches are available to enhance sleep 86 but have not been examined in clinical trials with cancer patients. Although commonly prescribed, data specific to the use of benzodiazepine and nonbenzodiazepine hypnotic drugs, sedating antidepressants, antipsychotics/neuroleptics, selected melatonin receptor agonists, and over-the-counter agents, including antihistamines, melatonin, and valerian, are currently insufficient to promote sleep quality in patients with cancer, including those at end of life. 87, 88 Meta-analyses suggest that hypnotic agents improve the quality and amount of sleep and reduce night awakenings in older adults with primary insomnia. [89] [90] [91] These benefits are outweighed by the associated adverse cognitive and psychomotor events, and daytime fatigue and sleepiness. 92 Pharmacologic agents indicated to improve sleep quality were categorized by the ONS PEP resources in the category of "Benefits Balanced with Harms," indicating that clinicians should evaluate the efficacy and safety of each prescribed agent to improve sleep in patients with cancer. 70 Several other pharmacologic therapies have shown potential to impact positively the cluster that includes poor sleep quality, fatigue, mood disturbance, and daytime sleepiness. Although agents to promote daytime functioning, such as bupropion sustained-release, methylphenidate, and donepezil, have been shown to improve fatigue, mood, and HRQOL in patients with cancer, [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] effects on sleep quality were not evaluated. Similarly, in 3 large randomized trials examining the effects of paroxetine in cancer patients during treatment, sleep quality was not measured. [103] [104] [105] However, in a small single-arm pilot study, paroxetine had positive effects on fatigue, mood, symptom distress, and sleep quality in women who had completed treatment for localized breast cancer and were experiencing hot flashes. 106 Two case reports and expert opinion identify benefits for modafinil in terms of sleep quality, symptom distress, and fatigue. [107] [108] [109] [110] [111] Although not approved by the US Food and Drug Administration (FDA), amisulpride has shown early promise in managing daytime sleepiness and fatigue secondary to sedating medications.
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Recommendations for Practice
Routine screening for sleep disturbances and fatigue should be integrated into clinical oncology practice. Positive screens must be followed up with assessment of risk factors for disturbed sleep, including other related symptoms, mood disturbances, and comorbid illness. 2 Referrals to sleep specialists are indicated when the clinical screen and assessment indicate the presence of sleep disorders or chronic insomnia, and when insomnia is refractory to usual intervention strategies. Oncology clinicians must be educated on basic strategies to recommend when transient or transient recurring insomnia is present. Although efficacy of the nonpharmacologic interventions presented in Table 2 awaits results of several ongoing randomized controlled trials, these interventions have been supported for introduction in clinical practice to treat chronic primary and secondary (comorbid) insomnia and fatigue, and optimize daytime function. 64, 69, 70 Although a wide variety of pharmacologic options are available to improve sleep quality, many are associated with adverse side effects. Little empiric evidence is available on the use of these agents in patients with cancer. Clinicians must be aware of a recent FDA warning about potential risks associated with sedative-hypnotic drugs, such as severe allergic reactions and complex sleep-related • Develop a nightly prebedtime routine.
• Keep the room dark, cool, and quiet; turn off phones; no computer or pets; use light clothing and covers. behaviors, including sleep-driving. 113 A table summarizing the medications commonly used to promote sleep is provided on the National Cancer Institute PDQ (Physician Data Query) Web site. 13 Prescribing considerations with these classes of agents include increased likelihood of problems with daytime sleepiness, fatigue, withdrawal symptoms, dependency, rebound insomnia, problems with sleep maintenance, memory problems, anticholinergic symptoms, orthostasis, and the potential for drug-drug interactions involving the cytochrome p450 isoenzyme system. 114 Increased public and professional education on sleep, sleep disturbances, and daytime consequences of sleep loss is recommended.
Recommendations for Research
Sleep disturbances in cancer patients and their impact on fatigue, daytime sleepiness, other symptoms, functioning, and HRQOL have emerged as recommended areas for research. The proceedings of 2 recent State of the Science conferences have highlighted the priorities for interdisciplinary research of sleep-wake disturbances in patients with chronic primary insomnia and those with cancer. 12, 30 Priority areas for research include evaluating the effectiveness of single-and multicomponent psychological and cognitive-behavioral treatments in not only reducing insomnia but also improving fatigue, daytime function, and HRQOL. Areas of particular focus for researchers include determining the cause of disturbed sleep associated with various tumor sites, disease stages, and treatment regimens; exploring the relationships among symptoms that cluster together with sleep disturbances and fatigue; and improving sleep outcome measures in clinical practice and research trials. 12 Relevant outcomes in clinical trials of therapies to improve sleep include short-and long-term effectiveness and associated risks/benefits, costs, and patient satisfaction. 64 
Summary
Increased knowledge and awareness are needed of available, evidence-based interventions to optimize sleep quality and improve fatigue and daytime sleepiness in adult cancer patients. Routine screening, assessment, and referrals can help identify individuals with sleep disturbances. Clinicians are encouraged to use recommended nonpharmacologic and pharmacologic interventions that are designed to optimize sleep quality and modify fatigue during and after cancer treatment.
